Revealing cerebrospinal fluid biomarkers in Parkinson's disease dementia based on iTRAQ proteomics research
IGFBP3 warrants further investigation as a diagnostic biomarker and therapeutic target for PDD, necessitating future validation in larger cohorts and <i>in vivo</i> models.
Authors
- Lijuan Mo (ORCID: https://orcid.org/0000-0003-1204-437X)
- L.X. Chen
- Guofen Zeng (ORCID: https://orcid.org/0009-0000-4275-6269)
- Changhong Tan (ORCID: https://orcid.org/0000-0002-8910-701X)
- Lin Han (ORCID: https://orcid.org/0000-0001-9788-9974)
- Peng Ma (ORCID: https://orcid.org/0000-0001-7125-8891)
- Huahua Su (ORCID: https://orcid.org/0009-0007-6653-6536)
- Jianhe Yue
- Xi Liu (ORCID: https://orcid.org/0000-0002-4785-2468)
- Ying Liu (ORCID: https://orcid.org/0000-0002-7164-962X)
Institutions
- Dalian Medical University (CN)
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Second Affiliated Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Frontiers in Neuroscience
- Published
- 2025-11-07
- DOI
- https://doi.org/10.3389/fnins.2025.1682274
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing
- Centre Scientifique et Technique du Bâtiment